AFN-1252 is a potent inhibitor of enoyl-ACP reductase fromBurkholderia pseudomallei-Crystal structure, mode of action, and biological activity

Discovery of azetidine based ene-amides as potent bacterial enoyl ACP reductase (FabI) inhibitors

(2014) Mohamed Takhi et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Treatment and prophylaxis of melioidosis

(2014) David Dance   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Rational Design of Broad Spectrum Antibacterial Activity Based on a Clinically Relevant Enoyl-Acyl Carrier Protein (ACP) Reductase Inhibitor

(2014) Johannes Schiebel et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Type II Fatty Acid Synthesis Is Essential for the Replication ofChlamydia trachomatis

(2014) Jiangwei Yao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Clinical Definitions of Melioidosis

(2013) Allen C. Cheng et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

The Burkholderia pseudomallei Enoyl-Acyl Carrier Protein Reductase FabI1 Is Essential forIn VivoGrowth and Is the Target of a Novel Chemotherapeutic with Efficacy

(2013) Jason E. Cummings et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects

(2013) Nachum Kaplan et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

New drugs for methicillin-resistant Staphylococcus aureus: an update

(2013) K. Kumar et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Resistance to AFN-1252 Arises from Missense Mutations inStaphylococcus aureusEnoyl-acyl Carrier Protein Reductase (FabI)

(2013) Jiangwei Yao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Activity of AFN-1252, a novel FabI inhibitor, againstStaphylococcus aureusin anin vitropharmacodynamic model simulating human pharmacokinetics

(2013) Brian T Tsuji et al.   JOURNAL OF CHEMOTHERAPY

Mode of Action,In VitroActivity, andIn VivoEfficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor

(2012) Nachum Kaplan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mechanisms of antibiotic resistance inBurkholderia pseudomallei: implications for treatment of melioidosis

(2012) Herbert P Schweizer   Future Microbiology

From Triclosan toward the Clinic: Discovery of Nonbiocidal, Potent FabI Inhibitors for the Treatment of Resistant Bacteria

(2012) Vincent Gerusz et al.   JOURNAL OF MEDICINAL CHEMISTRY

Melioidosis

(2012) W. Joost Wiersinga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evolution of Burkholderia pseudomallei in Recurrent Melioidosis

(2012) Hillary S. Hayden et al.   PLoS One

Development of ceftazidime resistance in an acute Burkholderia pseudomallei infection

(2012) Sarovich et al.   Infection and Drug Resistance

Melioidosis: a clinical overview

(2011) D. Limmathurotsakul et al.   BRITISH MEDICAL BULLETIN

Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery?

(2011) Joshua B Parsons et al.   CURRENT OPINION IN MICROBIOLOGY

Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei

(2011) N. Liu et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors

(2011) J. B. Parsons et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Features and development ofCoot

(2010) P. Emsley et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Mechanism and Inhibition of the FabV Enoyl-ACP Reductase fromBurkholderia mallei

(2010) Hao Lu et al.   BIOCHEMISTRY

Present and future therapeutic strategies for melioidosis and glanders

(2010) D Mark Estes et al.   Expert Review of Anti-Infective Therapy

AFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity

(2009) J. A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens

(2009) Sophie Brinster et al.   NATURE

Inhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway

(2008) Hao Lu et al.   ACCOUNTS OF CHEMICAL RESEARCH

Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances

(2008) Irith Wiegand et al.   Nature Protocols